The company said net product revenues rose to $2.8 billion in Q3 2024 from $2.5 billion in Q3 2023, citing higher TRIKAFTA/KAFTRIO product revenues and higher net realized pricing in the U.S. as the drivers.

1. 01

   The company said net product revenues rose to $2.8 billion in Q3 2024 from $2.5 billion in Q3 2023, citing higher TRIKAFTA/KAFTRIO product revenues and higher net realized pricing in the U.S. as the drivers.

2. 02

   The company said AIPR&D was not significant in Q3 2024, but that it included $4.4 billion related to its acquisition of Alpine Immune Sciences, which was accounted for as an asset acquisition, in the 9 months ended May 2024.

3. 03

   The company said its total cash, cash equivalents and marketable securities decreased to $11.2 billion as of September 30, 2024 from $13.7 billion as of December 31, 2023, citing cash paid to acquire Alpine and share repurchases as the drivers.

4. 04

   The company said total research and development and selling, general and administrative expenses rose to $1.2 billion in Q3 2024 from $1.1 billion in Q3 2023, citing increased commercial investments to support global launches and continued investment in mid-to-late stage therapies.

Key figures

Quarter ended September 30, 2024

Revenue

$2.8B

Operating income

$1.1B

Net income

$1.0B

EPS

$4.01

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.